Thus, the inhibitory drug of the RRM2B activity could be of potential use to treat Alzheimer's disease and particularly gemcitabine might be considered as a promising candidate to be repurposed for its treatment. This evidence concerns the gene RRM2B and early-onset autosomal dominant Alzheimer disease.